Literature DB >> 9790878

Purification of recombinant Rous sarcoma virus integrase possessing physical and catalytic properties similar to virion-derived integrase.

M McCord1, S J Stahl, T C Mueser, C C Hyde, A C Vora, D P Grandgenett.   

Abstract

Recombinant Rous sarcoma virus integrase cloned from the Prague A (PrA) virus strain was expressed in Escherichia coli. Here we report the detailed purification procedure resulting in an apparently homogeneous integrase. Recombinant PrA integrase was compared at both the protein structural and the catalytic levels to avian myeloblastosis virus integrase purified from virions. Both proteins exist minimally in a dimeric state at low nanomolar concentrations as analyzed by glycerol gradient sedimentation and protein crosslinking studies. Likewise, both proteins have similar specific activities for full-site (concerted integration reaction) and half-site strand transfer activities using linear 480-bp retrovirus-like donor substrates that contain wild-type or mutant termini. They respond similarly to high NaCl concentrations ( approximately 350 mM) as well as aprotic solvents for efficient full-site strand transfer. The data suggest that recombinant integrase proteins with physical and catalytic properties similar to the virion counterpart can be purified using these techniques and will faithfully and efficiently promote the full-site integration reaction in vitro. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790878     DOI: 10.1006/prep.1998.0954

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  15 in total

1.  DNase protection analysis of retrovirus integrase at the viral DNA ends for full-site integration in vitro.

Authors:  A Vora; D P Grandgenett
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Correct integration of model substrates by Ty1 integrase.

Authors:  S P Moore; D J Garfinkel
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Biochemical and biophysical analyses of concerted (U5/U3) integration.

Authors:  Duane P Grandgenett; Sibes Bera; Krishan K Pandey; Ajaykumar C Vora; Jacob Zahm; Sapna Sinha
Journal:  Methods       Date:  2008-11-29       Impact factor: 3.608

4.  Differential assembly of Rous sarcoma virus tetrameric and octameric intasomes is regulated by the C-terminal domain and tail region of integrase.

Authors:  Sibes Bera; Krishan K Pandey; Hideki Aihara; Duane P Grandgenett
Journal:  J Biol Chem       Date:  2018-09-05       Impact factor: 5.157

5.  A C-terminal "Tail" Region in the Rous Sarcoma Virus Integrase Provides High Plasticity of Functional Integrase Oligomerization during Intasome Assembly.

Authors:  Krishan K Pandey; Sibes Bera; Ke Shi; Hideki Aihara; Duane P Grandgenett
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

6.  Efficient concerted integration by recombinant human immunodeficiency virus type 1 integrase without cellular or viral cofactors.

Authors:  Sapna Sinha; Michael H Pursley; Duane P Grandgenett
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Assembly and catalysis of concerted two-end integration events by Moloney murine leukemia virus integrase.

Authors:  F Yang; M J Roth
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Avian retrovirus DNA internal attachment site requirements for full-site integration in vitro.

Authors:  R Chiu; D P Grandgenett
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Differential multimerization of Moloney murine leukemia virus integrase purified under nondenaturing conditions.

Authors:  Rodrigo A Villanueva; Colleen B Jonsson; Jennifer Jones; Millie M Georgiadis; Monica J Roth
Journal:  Virology       Date:  2003-11-10       Impact factor: 3.616

10.  Molecular and genetic determinants of rous sarcoma virus integrase for concerted DNA integration.

Authors:  Roger Chiu; Duane P Grandgenett
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.